News

Case Studies Highlight Diversity of Rheumatoid Arthritis-Associated PH

A recent article that presented case studies of three patients with rheumatoid arthritis-associated pulmonary hypertension (PH), highlights the diversity of the underlying causes of the disease, and emphasizes the importance of diagnosing it early. The study “Rheumatoid arthritis associated pulmonary hypertension: Clinical challenges reflecting the diversity of pathophysiology”…

Screening for PAH in Systemic Sclerosis Patients May Improve Health-related Outcomes

Screening patients with systemic sclerosis (SSc) for pulmonary arterial hypertension (PAH) may help identify patients with both conditions sooner to start appropriate treatments, ensuring a better outcome, according to new research. The study, “Epidemiology And Disease Characteristics Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension: Results From A Real-Life Screening Programme,” was published in…

Analysis Ranks Letairis Best Endothelin Receptor Antagonist for PAH Treatment

Letairis (ambrisentan) was the most efficient, robust therapeutic among endothelin receptor antagonists (ERAs) to treat pulmonary arterial hypertension (PAH), according to a study that compared the drug to three other therapies: Thelin (sitaxsentan), Tracleer (bosentan) and Opsumit (macitentan). The study, “Comparative efficacy and acceptability of endothelin receptor antagonists for…

PH Screening Can Be Given Only to Premature Babies with Risk Factors, Study Suggests

Researchers suggest that routine echocardiographic (ECG) screening for pulmonary hypertension (PH) in premature infants might only be needed if certain risk factors are evident. While the proposed approach would identify most children affected and be of help to hospitals, researchers acknowledge that lung hypertension might go undetected in some babies. The change is estimated to…